These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

98 related articles for article (PubMed ID: 19352302)

  • 1. Chemotherapy-induced tumor gene expression changes in human breast cancers.
    Lee SC; Xu X; Lim YW; Iau P; Sukri N; Lim SE; Yap HL; Yeo WL; Tan P; Tan SH; McLeod H; Goh BC
    Pharmacogenet Genomics; 2009 Mar; 19(3):181-92. PubMed ID: 19352302
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Possible involvement of CCT5, RGS3, and YKT6 genes up-regulated in p53-mutated tumors in resistance to docetaxel in human breast cancers.
    Ooe A; Kato K; Noguchi S
    Breast Cancer Res Treat; 2007 Mar; 101(3):305-15. PubMed ID: 16821082
    [TBL] [Abstract][Full Text] [Related]  

  • 3. cDNA microarray analysis of isogenic paclitaxel- and doxorubicin-resistant breast tumor cell lines reveals distinct drug-specific genetic signatures of resistance.
    Villeneuve DJ; Hembruff SL; Veitch Z; Cecchetto M; Dew WA; Parissenti AM
    Breast Cancer Res Treat; 2006 Mar; 96(1):17-39. PubMed ID: 16322897
    [TBL] [Abstract][Full Text] [Related]  

  • 4. miRNA-34a is associated with docetaxel resistance in human breast cancer cells.
    Kastl L; Brown I; Schofield AC
    Breast Cancer Res Treat; 2012 Jan; 131(2):445-54. PubMed ID: 21399894
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Influence of TP53 gene alterations and c-erbB-2 expression on the response to treatment with doxorubicin in locally advanced breast cancer.
    Geisler S; Lønning PE; Aas T; Johnsen H; Fluge O; Haugen DF; Lillehaug JR; Akslen LA; Børresen-Dale AL
    Cancer Res; 2001 Mar; 61(6):2505-12. PubMed ID: 11289122
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Changes in gene expression associated with response to neoadjuvant chemotherapy in breast cancer.
    Hannemann J; Oosterkamp HM; Bosch CA; Velds A; Wessels LF; Loo C; Rutgers EJ; Rodenhuis S; van de Vijver MJ
    J Clin Oncol; 2005 May; 23(15):3331-42. PubMed ID: 15908647
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Genomic predictors of response to doxorubicin versus docetaxel in primary breast cancer.
    Martin M; Romero A; Cheang MC; López García-Asenjo JA; García-Saenz JA; Oliva B; Román JM; He X; Casado A; de la Torre J; Furio V; Puente J; Caldés T; Vidart JA; Lopez-Tarruella S; Diaz-Rubio E; Perou CM
    Breast Cancer Res Treat; 2011 Jul; 128(1):127-36. PubMed ID: 21465170
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Gene expression analysis of drug-resistant MCF-7 cells: implications for relation to extracellular matrix proteins.
    Işeri OD; Kars MD; Arpaci F; Gündüz U
    Cancer Chemother Pharmacol; 2010 Feb; 65(3):447-55. PubMed ID: 19543729
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A novel group of genes regulates susceptibility to antineoplastic drugs in highly tumorigenic breast cancer cells.
    Mallory JC; Crudden G; Oliva A; Saunders C; Stromberg A; Craven RJ
    Mol Pharmacol; 2005 Dec; 68(6):1747-56. PubMed ID: 16150928
    [TBL] [Abstract][Full Text] [Related]  

  • 10. HER-2/neu as a predictive marker in a population of advanced breast cancer patients randomly treated either with single-agent doxorubicin or single-agent docetaxel.
    Di Leo A; Chan S; Paesmans M; Friedrichs K; Pinter T; Cocquyt V; Murray E; Bodrogi I; Walpole E; Lesperance B; Korec S; Crown J; Simmonds P; Von Minckwitz G; Leroy JY; Durbecq V; Isola J; Aapro M; Piccart MJ; Larsimont D
    Breast Cancer Res Treat; 2004 Aug; 86(3):197-206. PubMed ID: 15567936
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evasion of a single-step, chemotherapy-induced senescence in breast cancer cells: implications for treatment response.
    Elmore LW; Di X; Dumur C; Holt SE; Gewirtz DA
    Clin Cancer Res; 2005 Apr; 11(7):2637-43. PubMed ID: 15814644
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prediction of doxorubicin sensitivity in breast tumors based on gene expression profiles of drug-resistant cell lines correlates with patient survival.
    Györffy B; Serra V; Jürchott K; Abdul-Ghani R; Garber M; Stein U; Petersen I; Lage H; Dietel M; Schäfer R
    Oncogene; 2005 Nov; 24(51):7542-51. PubMed ID: 16044152
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Drug resistant breast cancer cells overexpress ETS1 gene.
    Kars MD; Işeri OD; Gündüz U
    Biomed Pharmacother; 2010 Sep; 64(7):458-62. PubMed ID: 20392592
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Altered expression of proliferation-inducing and proliferation-inhibiting genes might contribute to acquired doxorubicin resistance in breast cancer cells.
    Saleh EM; El-Awady RA; Abdel Alim MA; Abdel Wahab AH
    Cell Biochem Biophys; 2009; 55(2):95-105. PubMed ID: 19593673
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Docetaxel versus doxorubicin in patients with metastatic breast cancer who have failed alkylating chemotherapy: a preliminary report of the randomized phase III trial. 303 Study Group.
    Aapro M
    Semin Oncol; 1998 Oct; 25(5 Suppl 12):7-11. PubMed ID: 9865705
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Gene expression profiling of breast tumor cell lines to predict for therapeutic response to microtubule-stabilizing agents.
    Kadra G; Finetti P; Toiron Y; Viens P; Birnbaum D; Borg JP; Bertucci F; Gonçalves A
    Breast Cancer Res Treat; 2012 Apr; 132(3):1035-47. PubMed ID: 21792624
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Moderate increase in Mdr1a/1b expression causes in vivo resistance to doxorubicin in a mouse model for hereditary breast cancer.
    Pajic M; Iyer JK; Kersbergen A; van der Burg E; Nygren AO; Jonkers J; Borst P; Rottenberg S
    Cancer Res; 2009 Aug; 69(16):6396-404. PubMed ID: 19654309
    [TBL] [Abstract][Full Text] [Related]  

  • 18. REIC/Dkk-3 overexpression downregulates P-glycoprotein in multidrug-resistant MCF7/ADR cells and induces apoptosis in breast cancer.
    Kawasaki K; Watanabe M; Sakaguchi M; Ogasawara Y; Ochiai K; Nasu Y; Doihara H; Kashiwakura Y; Huh NH; Kumon H; Date H
    Cancer Gene Ther; 2009 Jan; 16(1):65-72. PubMed ID: 18654608
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Post-treatment tumor gene expression signatures are more predictive of treatment outcomes than baseline signatures in breast cancer.
    Lee SC; Xu X; Chng WJ; Watson M; Lim YW; Wong CI; Iau P; Sukri N; Lim SE; Yap HL; Buhari SA; Tan P; Guo J; Chuah B; McLeod HL; Goh BC
    Pharmacogenet Genomics; 2009 Nov; 19(11):833-42. PubMed ID: 19809382
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Systematic analysis of gene expression pattern in has-miR-760 overexpressed resistance of the MCF-7 human breast cancer cell to doxorubicin.
    Lv J; Fu Z; Shi M; Xia K; Ji C; Xu P; Lv M; Pan B; Dai L; Xie H
    Biomed Pharmacother; 2015 Feb; 69():162-9. PubMed ID: 25661353
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.